Lenco Laboratories recently appeared in PR Newswire for its partnership with CompuGroup Medical in launching a successful COVID-19 testing program:
The leading global healthcare technology company, CompuGroup Medical (CGM), assisted Lenco Diagnostic Laboratory (Lenco) with the launch of its successful COVID-19 testing program on March 19. Since then, Lenco has delivered test results for thousands of New Yorkers every day.
"In the month of July, we ran 49,788 COVID-19 PCR tests on patients from doctors' offices, nursing homes, and local hospitals," said Felix Sandler, Chief Information Officer of Lenco. "CGM was instrumental in quickly setting up instrument interfaces and resolving any production issues to facilitate the rapid ramp-up of testing."
Important Links and Updates about COVID-19
Centers for Disease Control and Prevention
U.S. Food and Drug Administration
New York State Department of Health
Lenco is a full-service clinical reference laboratory offering clinical diagnostics at its best. The laboratory is renowned for excellence and expertise with Lenco’s highly dedicated team of specialists in the field who possess experience, professionalism and dedication. Lenco continuously meets the needs of their physician clients and their patients and is committed to being one of the top leading laboratories in a world of rapidly advancing diagnostic technology. To learn more about Lenco, visit www.lencolab.com.
Note: Please contact your referring physician for any questions about your test results. To view your test results, click here.
BROOKLYN, N.Y., July 6, 2020 /PRNewswire/ -- Beckman Coulter and Lenco Diagnostic Laboratories (Lenco), one of NYC's largest privately-owned full-service reference laboratories, today announced that the first shipment of 40,000 of Beckman Coulter's new Access SARS-CoV-2 IgG Antibody tests has arrived in New York City to help battle the COVID-19 outbreak, with 20,000 additional tests anticipated each week.
Lenco was among the first clinical labs to receive a shipment of the new Beckman Coulter SARS-CoV-2 IgG antibody test. The Beckman Coulter COVID-19 serology test is one of the most accurate and high-quality tests available in the U.S., and has 100% Positive Percent Agreement (sensitivity) and a confirmed 99.6% Negative Percent Agreement (specificity).
Lenco Diagnostic Laboratories (Lenco), one of NYC's largest privately-owned full service reference laboratories, provides an update on COVID-19 testing and recently launched IgG and IgM serology testing to detect antibodies against COVID-19.
In mid-March, Lenco became one of the first 28 approved New York laboratories to start testing for COVID-19 with a molecular based assay utilizing PCR technology for the qualitative detection of nucleic acid in respiratory specimens in patients who meet the Centers for Disease Control and Prevention criteria.
Brooklyn, NY (April 16, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full-service clinical laboratories, today announced the launch of antibody testing for coronavirus (COVID-19).
“In the last several weeks, Lenco has been diligently working with trusted partners to launch a test that will detect the presence of IgG and IgM antibodies produced by the body in response to the SARS-CoV-2 virus,” stated Dennis Tilman, Chief Operating Officer of Lenco. “We are hopeful the knowledge obtained from these tests will help both physicians and patients in the management and care of this novel virus. Lenco is proud to expand its diagnostic capabilities and will continue to contribute to the needs of the community.”
Brooklyn, NY (April 14, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full service clinical laboratories, today announced it is currently working with trusted manufacturing partners to launch IgG and IgM serology tests that will be used to detect antibodies through blood against SARS-CoV-2 virus that causes COVID-19 infection.
Brooklyn, NY (March 20, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full service clinical laboratories, has launched testing for coronavirus (COVID-19).
Lenco performs high-throughput, automated Real-Time RT-PCR diagnostic testing intended for the qualitative detection of COVID-19. This test is to be performed only using respiratory specimens collected from individuals who meet COVID-19 clinical and/or epidemiological criteria for testing.
Brooklyn, NY (March 9, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC’s largest privately-owned full service reference laboratories, announced it is currently working with trusted manufacturing partners to launch a new coronavirus disease 2019 (COVID-19) test. The test will aid in detection of the underlying novel coronavirus that causes COVID-19 and will be used with patients who meet the Centers for Disease Control and Prevention (CDC) clinical criteria for testing.
Novel coronavirus has been identified as the cause of a disease outbreak in Wuhan, China. COVID-19, causing pneumonia-like symptoms, can spread from person to person. The risk of infection for COVID-19 is higher for older adults and those who have serious chronic medical conditions. The virus can easily be transmitted between people as close as six feet within distance of each other through respiratory droplets produced when coughing or sneezing.
October marks the beginning of flu season. As in previous years, flu cases are expected to peak between December and February, and taper off around May. While most cases of the “flu” are diagnosed and treated empirically, based on the common symptoms with which it usually presents (fever, headache, sore throat, cough, runny nose, as well as body aches being the most common ones), this is obviously not a 100% accurate method of diagnosis. Instead, physicians should consider using molecular influenza assays to get an accurate diagnosis, especially in the case of patients with complications.
Brooklyn, NY (September 19, 2019) - Lenco Diagnostic Laboratories (Lenco) has introduced a new testing technology platform for detecting and reporting UTIs faster. The BacterioScan platform will enable the lab to offer clinicians best-in-the-industry turnaround times in determining the presence of infection.
The Best Diagnostics for More of Your Patients – Lenco & Aetna’s NEW Partnership Brooklyn, NY (August 1, 2018) – Lenco Diagnostic Laboratories (Lenco) became a national, in-network, preferred lab provider with Aetna!